CY1122358T1 - C-τελικοι hsp90 αναστολεις - Google Patents

C-τελικοι hsp90 αναστολεις

Info

Publication number
CY1122358T1
CY1122358T1 CY20191101180T CY191101180T CY1122358T1 CY 1122358 T1 CY1122358 T1 CY 1122358T1 CY 20191101180 T CY20191101180 T CY 20191101180T CY 191101180 T CY191101180 T CY 191101180T CY 1122358 T1 CY1122358 T1 CY 1122358T1
Authority
CY
Cyprus
Prior art keywords
hsp90 inhibitors
terminal hsp90
terminal
compounds
inhibitors
Prior art date
Application number
CY20191101180T
Other languages
English (en)
Inventor
Brian S.J. BLAGG
Bhaskar Reddy KUSUMA
Teather SUNDSTROM
Original Assignee
The University Of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Kansas filed Critical The University Of Kansas
Publication of CY1122358T1 publication Critical patent/CY1122358T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

Παρέχονται Hsp90 C-τελικοί αναστολείς και φαρμακευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις. Οι ενώσεις της αποκάλυψης είναι χρήσιμες για τη θεραπευτική αγωγή και/ή πρόληψη νευροεκφυλιστικών διαταραχών όπως διαβητική περιφερική νευροπάθεια.
CY20191101180T 2012-02-09 2019-11-11 C-τελικοι hsp90 αναστολεις CY1122358T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597004P 2012-02-09 2012-02-09
PCT/US2013/025387 WO2013119985A1 (en) 2012-02-09 2013-02-08 C-terminal hsp90 inhibitors

Publications (1)

Publication Number Publication Date
CY1122358T1 true CY1122358T1 (el) 2021-01-27

Family

ID=47754998

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101180T CY1122358T1 (el) 2012-02-09 2019-11-11 C-τελικοι hsp90 αναστολεις

Country Status (24)

Country Link
US (6) US9422320B2 (el)
EP (2) EP3656758B1 (el)
JP (1) JP6121450B2 (el)
KR (1) KR102124109B1 (el)
CN (2) CN104271587B (el)
AU (1) AU2013216858C1 (el)
BR (1) BR112014019704B1 (el)
CA (1) CA2866814C (el)
CY (1) CY1122358T1 (el)
DK (2) DK2812341T3 (el)
EA (1) EA027147B1 (el)
ES (1) ES2755093T3 (el)
FI (1) FI3656758T3 (el)
HK (2) HK1205131A1 (el)
HR (1) HRP20191940T1 (el)
HU (1) HUE046939T2 (el)
LT (1) LT2812341T (el)
MX (1) MX361233B (el)
NZ (1) NZ629778A (el)
PL (1) PL2812341T3 (el)
PT (2) PT2812341T (el)
RS (1) RS59719B1 (el)
SI (1) SI2812341T1 (el)
WO (1) WO2013119985A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3656758B1 (en) 2012-02-09 2024-03-06 The University of Kansas Intermediates for the preparation of c-terminal hsp90 inhibitors
US9994556B2 (en) 2014-06-13 2018-06-12 University Of Kansas Triazole modified coumarin and biphenyl amide-based HSP90 inhibitors
NZ728482A (en) 2014-06-24 2022-11-25 Univ Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
WO2016145219A1 (en) * 2015-03-10 2016-09-15 University Of Florida Research Foundation, Inc. Treatment of peripheral neuropathies
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina
MX2020012366A (es) * 2018-05-14 2021-02-09 Reata Pharmaceuticals Inc Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
EP1807440B1 (en) 2004-11-03 2020-02-19 The University of Kansas Novobiocin analogues as anticancer agents
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8846742B2 (en) * 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2131656A4 (en) 2006-11-15 2011-12-07 Forest Lab Holdings Ltd phthalazine
KR101313804B1 (ko) 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
US20130116227A1 (en) 2010-07-13 2013-05-09 Dainippon Sumitomo Pharma Co., Ltd. Biaryl amide derivative or pharmaceutically acceptable salt thereof
CN101967125B (zh) * 2010-10-08 2012-07-04 广州暨南生物医药研究开发基地有限公司 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用
AU2012240079B2 (en) 2011-04-05 2017-05-18 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2012162054A1 (en) 2011-05-20 2012-11-29 The University Of Kansas Dynamic inhibitors of heat shock protein 90
EP3656758B1 (en) 2012-02-09 2024-03-06 The University of Kansas Intermediates for the preparation of c-terminal hsp90 inhibitors
EP3066072B1 (en) 2013-11-07 2021-11-03 The University of Kansas Biphenylamide derivative hsp90 inhibitors
US10030006B2 (en) 2013-11-11 2018-07-24 University Of Kansas Coumarin based Hsp90 inhibitors with urea and ether substituents
US9994556B2 (en) 2014-06-13 2018-06-12 University Of Kansas Triazole modified coumarin and biphenyl amide-based HSP90 inhibitors
NZ728482A (en) 2014-06-24 2022-11-25 Univ Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers

Also Published As

Publication number Publication date
PL2812341T3 (pl) 2020-03-31
HK1205131A1 (en) 2015-12-11
AU2013216858C1 (en) 2018-03-01
JP6121450B2 (ja) 2017-04-26
US10590157B2 (en) 2020-03-17
AU2013216858A1 (en) 2014-09-18
NZ629778A (en) 2016-03-31
PT3656758T (pt) 2024-03-27
HRP20191940T1 (hr) 2020-01-10
ES2755093T3 (es) 2020-04-21
FI3656758T3 (fi) 2024-04-22
EA201491496A1 (ru) 2015-01-30
EP3656758A1 (en) 2020-05-27
US11390640B2 (en) 2022-07-19
CA2866814A1 (en) 2013-08-15
EA027147B1 (ru) 2017-06-30
US10882881B2 (en) 2021-01-05
CN107474085B (zh) 2021-05-11
BR112014019704B1 (pt) 2022-05-31
RS59719B1 (sr) 2020-01-31
US20190023730A1 (en) 2019-01-24
BR112014019704A2 (el) 2017-06-20
MX361233B (es) 2018-11-30
EP3656758B1 (en) 2024-03-06
US20210188891A1 (en) 2021-06-24
WO2013119985A1 (en) 2013-08-15
LT2812341T (lt) 2019-12-10
AU2013216858B2 (en) 2017-08-24
JP2015506982A (ja) 2015-03-05
HK1249519A1 (zh) 2018-11-02
CN104271587B (zh) 2017-09-12
EP2812341B1 (en) 2019-08-28
KR20150001729A (ko) 2015-01-06
US20230102047A1 (en) 2023-03-30
SI2812341T1 (sl) 2020-02-28
DK3656758T3 (da) 2024-04-22
HUE046939T2 (hu) 2020-04-28
CA2866814C (en) 2021-02-16
EP2812341A1 (en) 2014-12-17
MX2014009608A (es) 2015-05-20
KR102124109B1 (ko) 2020-06-17
US20200283465A1 (en) 2020-09-10
US20170051000A1 (en) 2017-02-23
US10030041B2 (en) 2018-07-24
BR112014019704A8 (pt) 2017-07-11
CN104271587A (zh) 2015-01-07
PT2812341T (pt) 2019-11-22
CN107474085A (zh) 2017-12-15
DK2812341T3 (da) 2019-11-18
US20150057240A1 (en) 2015-02-26
US9422320B2 (en) 2016-08-23

Similar Documents

Publication Publication Date Title
CY1122358T1 (el) C-τελικοι hsp90 αναστολεις
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
DOP2016000271A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
CY1120638T1 (el) Αναστολεις τυροσινικης κινασης πυριμιδινυλιου
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CY1119709T1 (el) Αντιμυκητιασικοι παραγοντες και χρησεις αυτων
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
CY1121550T1 (el) Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου